|
|
Volumn 22, Issue 6, 2004, Pages 641-
|
|
EGFR inhibitors square off at ASCO
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
ERLOTINIB;
GEFITINIB;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY H R3;
NIMOTUZUMAB;
PANITUMUMAB;
UNCLASSIFIED DRUG;
BRAIN CANCER;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CLINICAL TRIAL;
COLORECTAL CANCER;
DRUG MARKETING;
HEAD AND NECK CANCER;
HUMAN;
LUNG NON SMALL CELL CANCER;
NOTE;
PANCREAS CANCER;
PRIORITY JOURNAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
DRUG INDUSTRY;
ECONOMIC COMPETITION;
EPIDERMAL GROWTH FACTOR;
HUMANS;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 2542548148
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0604-641 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|